Impact News +++ Energy Fuels Aktie: Achtung, Aufholpotenzial! (Aktiencheck) +++ ENERGY FUELS Aktie -3,11%

CHEMOMAB Aktie

>CHEMOMAB Aktienkurs

1.08 EUR +5.9% (Tradegate)

Ask: 1.08 EUR / 1461 Stück

Bid: 1.04 EUR / 1535 Stück

Tagesumsatz: 100 Stück

Realtime Kurs von 8 bis 22 Uhr!

CHEMOMAB Aktie über LYNX handeln

Intraday

1 Jahr

>CHEMOMAB Performance

1 Woche: +9,1%

1 Monat: -9,2%

3 Monate: +12,5%

6 Monate: -49,1%

1 Jahr: +21,0%

laufendes Jahr: -43,5%

>CHEMOMAB Aktie

Name:

CHEMOMAB THERAP. ADR/20

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US16385C1045 / A3CMJ9

Symbol/ Ticker:

2QV0 (Frankfurt) / CMMB (NASDAQ)

Kürzel:

FRA:2QV0, ETR:2QV0, 2QV0:GR, NASDAQ:CMMB

Index:

Webseite:

https://www.chemomab.com/

Marktkapitalisierung:

19.83 Mio. EUR

Umsatz:

EBITDA:

-12.23 Mio. EUR

Gewinn je Aktie:

-0.476 EUR

Schulden:

0.25 Mio. EUR

Liquide Mittel:

9.14 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

- / 2.22 / -

Gewinnm./ Eigenkapitalr.:

- / -112.97%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

CHEMOMAB

Letzte Datenerhebung:

05.07.25

>CHEMOMAB Eigentümer

Aktien: 19.16 Mio. St.

f.h. Aktien: 263.06 Mio. St.

Insider Eigner: 15.27%

Instit. Eigner: 25.38%

Leerverk. Aktien: 0.83%

>CHEMOMAB Peer Group

APYX MEDICAL

COSMOS HEALTH

DIANTHUS

EQUILLIUM

EXAGEN

INOTIV

PLIANT THERAPEUTICS

PRECIGEN

RHOEN-KLINIKUM ADR

SILENCE THERAPEUTICS ADR

>CHEMOMAB Chart & Kurs - NASDAQ

>CHEMOMAB News

30.06.25 - 14:03	Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live′25 (GlobeNewswire EN)
	Positive nebokitug PSC Phase 2 data was presented in an oral session at BSG Live'25, the scientific meeting of the British Society for Gastroenterology....

15.05.25 - 14:03	Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	These major milestones in Q1 support advancement of Nebokitug to Phase 3 and position It to potentially become the first FDA-approved treatment for PSC....

28.04.25 - 14:03	Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug′s Impact in Primary Sclerosing Cholangitis and Related Diseases (GlobeNewswire EN)
	Chemomab reported new clinical data to be presented at EASL 2025 that further confirms the potential of nebokitug as a first-in-class treatment for PSC....

27.03.25 - 21:57	Chemomab Therapeutics Touts Positive Data From Experimental Drug For Chronic Liver Disease (Benzinga)
	Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers. read more...

27.03.25 - 13:33	Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers (GlobeNewswire EN)
	Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis....

03.03.25 - 15:27	Chemomab Therapeutics GAAP EPS of -$0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.25 - 14:03	Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire EN)
	In 2024 reported positive nebokitug Phase 2 primary sclerosing cholangitis data and aligned on a clear, efficient path to potential FDA regulatory approval...

19.02.25 - 13:03	Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis (GlobeNewswire EN)
	After End-of-Phase 2 meeting, Chemomab and FDA aligned on a clear pathway to regulatory approval—a single pivotal Phase 3 study for the treatment of PSC....

03.12.24 - 13:03	Chemomab to Participate in Oppenheimer′s Movers in Rare Disease Summit (GlobeNewswire EN)
	Chemomab management is participating in the Oppenheimer Movers in Rare Disease Summit on Dec 13, 2024 at the Westin Grand Central in NYC....

19.11.24 - 13:06	Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab′s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis (GlobeNewswire EN)
	Oral presentation at AASLD highlights broad clinical activity of Chemomab's CM-101 across multiple biomarkers and its disease-modifying potential in PSC...

14.11.24 - 23:36	Chemomab Therapeutics CEO Dr Adi Mor discusses Q3 results; progress with lead PSC treatment (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

14.11.24 - 16:03	Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.05 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.08.24 - 13:03	Chemomab Therapeutics to Present at September 2024 Investor Conferences (GlobeNewswire EN)
	Chemomab will be presenting at the HC Wainwright Global Investment Conference and the HBM Biopharma Summit in September...

26.08.24 - 17:18	Chemomab jumps on positive liver scarring trial results (Globes)
	Chemomab Therapeutics is developing a treatment for rare liver scarring disease PSC....

21.08.24 - 14:20	Chemomab Therapeutics Ltd reports results for the quarter ended in June - Earnings Summary (Reuters EN)
	Chemomab Therapeutics Ltd reports results for the quarter ended in June - Earnings Summary...

21.08.24 - 13:12	Chemomab Therapeutics GAAP EPS of -$0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.08.24 - 13:06	Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25....

12.08.24 - 13:03	Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update (GlobeNewswire EN)
	Chemomab will report its second quarter 2024 financial results and provide a business update on August 21, 2024 at 7:00am ET....

30.07.24 - 15:03	Chemomab Therapeutics Announces Closing of $10 Million Private Placement (GlobeNewswire EN)
	Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026...

26.07.24 - 13:09	Chemomab Therapeutics regains compliance with Nasdaq (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Kein Kaiser kann, was unser ist, verschenken. - Friedrich Johann Christoph Schiller

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram